, Guidelines for the treatment of malaria, 2010.

, WHO. Global Malaria Programme. World Malaria Report, 2014.

, Guidelines for the treatment of malaria, 2015.

L. K. Basco, J. Bickii, and P. Ringwald, In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon, Antimicrob Agents Chemother, vol.42, pp.2347-51, 1998.

B. Pradines, A. Tall, T. Fusai, A. Spiegel, R. Hienne et al., In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs, Antimicrob Agents Chemother, vol.43, pp.418-438, 1999.

H. Kaddouri, A. Djimdé, S. Dama, A. Kodio, M. Tekete et al., Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali, Int J Parasitol, vol.38, pp.791-799, 2008.

N. B. Quashie, N. O. Duah, B. Abuaku, L. Quaye, R. Ayanful-torgby et al., A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs, Malar J, vol.12, p.450, 2013.

B. Pradines, L. Bertaux, C. Pomares, P. Delaunay, and P. Marty, Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia, Malar J, vol.10, p.268, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00629634

C. Sisowath, J. Strömberg, A. Mårtensson, M. Msellem, C. Obondo et al., In vivo selection of Plasmodium falciparum pfmdr1 86 N coding alleles by artemether-lumefantrine (Coartem), J Infect Dis, vol.191, pp.1014-1021, 2005.

C. Sisowath, P. E. Ferreira, L. Y. Bustamante, S. Dahlström, A. Mårtensson et al., The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa, Trop Med Int Health, vol.12, pp.736-778, 2007.

F. N. Baliraine and P. J. Rosenthal, Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda, J Infect Dis, vol.204, pp.1120-1124, 2011.

C. T. Happi, G. O. Gbotosho, O. A. Folarin, A. Sowunmi, T. Hudson et al., Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria, Antimicrob Agents Chemother, vol.53, pp.888-95, 2009.

G. S. Humphreys, I. Merinopoulos, J. Ahmed, C. Whitty, T. K. Mutabingwa et al., Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria, Antimicrob Agents Chemother, vol.51, pp.991-998, 2007.

N. B. Gadalla, I. Adam, S. E. Elzaki, S. Bashir, I. Mukhtar et al., Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine, Antimicrob Agents Chemother, vol.55, pp.5408-5419, 2011.

M. Mungthin, R. Khositnithikul, N. Sitthichot, N. Suwandittakul, V. Wattanaveeradej et al., Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in thai isolates of Plasmodium falciparum, Am J Trop Med Hyg, vol.83, pp.1005-1014, 2010.

M. Hassan-alin, A. Björkman, and W. H. Wernsdorfer, Synergism of benflumetol and artemether in Plasmodium falciparum, Am J Trop Med Hyg, vol.61, pp.439-484, 1999.

A. M. Dondorp, F. Nosten, P. Yi, D. Das, W. Hanpithakpong et al., Artemisinin resistance in Plasmodium falciparum malaria, N Engl J Med, vol.361, pp.455-67, 2012.

B. Witkowski, J. Lelièvre, M. J. Barragán, V. Laurent, X. Z. Su et al., Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism, Antimicrob Agents Chemother, vol.54, pp.1872-1879, 2010.

H. Noedl, Y. Se, K. Schaecher, B. L. Smith, D. Socheat et al., Evidence of artemisinin-resistant malaria in western Cambodia, N Engl J Med, vol.359, pp.2619-2639, 2008.

B. Witkowski, N. Khim, P. Chim, S. Kim, S. Ke et al., Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in Western Cambodia, Antimicrob Agents Chemother, vol.57, pp.914-937, 2013.

B. Witkowski, C. Amaratunga, N. Khim, S. Sreng, P. Chim et al., Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in vitro and ex vivo drug-response studies, Lancet Infect Dis, vol.13, pp.1043-1052, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-00863935

C. Amaratunga, A. T. Neal, and R. M. Fairhurst, Flow cytometry-based analysis of artemisinin-resistant Plasmodium falciparum in the ring-stage survival assay, Antimicrob Agents Chemother, vol.58, pp.4938-4978, 2014.

S. Takala-harrison, T. G. Clark, C. G. Jacob, M. P. Cummings, O. Miotto et al., Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia, Proc Natl Acad Sci USA, vol.110, pp.240-245, 2013.

F. Ariey, B. Witkowski, C. Amaratunga, J. Beghain, A. Langlois et al., A molecular marker of artemisinin-resistant Plasmodium falciparum malaria, Nature, vol.505, pp.50-55, 2014.
URL : https://hal.archives-ouvertes.fr/pasteur-00921203

S. Abdulla, I. Sagara, S. Borrmann, D. '-alessandro, U. González et al., Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial, Lancet, vol.372, pp.1819-1846, 2008.

A. Nhama, Q. Bassat, S. Enosse, A. Nhacolo, R. Mutemba et al., In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique, Malar J, vol.13, p.309, 2014.

J. L. Ndiaye, M. Randrianarivelojosia, I. Sagara, P. Brasseur, I. Ndiaye et al., Randomized, multicentre assessment of the efficacy and safety of ASAQ-a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria, Malar J, vol.8, p.125, 2009.

P. Chanda, M. Hawela, M. Kango, and N. Sipilanyambe, Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Coartesiane) for the treatment of uncomplicated Plasmodium falciparum in children in Zambia, Malar J, vol.5, p.75, 2006.

I. Van-den-broek, C. Kitz, A. Attas, S. Libama, F. Balasegaram et al., Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo, Malar J, vol.5, p.113, 2006.

I. Sagara, A. Diallo, M. Kone, M. Coulibaly, S. I. Diawara et al., A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali, Am J Trop Med Hyg, vol.79, pp.655-61, 2008.

I. Sagara, A. Dicko, A. Djimde, O. Guindo, M. Kone et al., A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, Am J Trop Med Hyg, vol.75, pp.630-636, 2006.

I. Sagara, A. H. Beavogui, I. Zongo, I. Soulama, I. Borghini-fuhrer et al., Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial, Lancet Infect Dis, vol.16, pp.189-98, 2015.

R. E. Desjardins, C. J. Canfield, J. D. Haynes, and J. D. Chulay, Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique, Antimicrob Agents Chemother, vol.16, pp.710-718, 1979.

. Icestimator,

A. Djimdé, O. K. Doumbo, J. F. Cortese, K. Kayentao, S. Doumbo et al., A molecular marker for chloroquine-resistant falciparum malaria, N Engl J Med, vol.344, pp.257-63, 2001.

A. Ouattara, A. Kone, M. Adams, B. Fofana, A. W. Maiga et al., Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara. Mali, Am J Trop Med Hyg, vol.92, pp.1202-1208, 2015.

E. H. Ekland and D. A. Fidock, In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes, Int J Parasitol, vol.38, pp.743-750, 2008.

B. Fall, S. Diawara, K. Sow, E. Baret, B. Diatta et al., Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs, Malar J, vol.10, p.310, 2011.

B. Fall, C. Camara, M. Fall, A. Nakoulima, P. Dionne et al., Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season, Malar J, vol.14, p.60, 2015.
DOI : 10.1186/s12936-015-0589-3

URL : https://hal.archives-ouvertes.fr/hal-01220028

J. B. Pilz, G. Wernsdorfer, J. Sirichaisinthop, C. Rojanawatsirivet, G. Wiedermann et al., In vitro sensitivity of Plasmodium falciparum to lumefantrine in north-western Thailand, Wien Klin Wochenschr, vol.116, pp.41-47, 2004.

K. Kayentao, O. K. Doumbo, L. K. Pénali, A. T. Offianan, K. M. Bhatt et al., Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial, Malar J, vol.11, p.364, 2012.

A. W. Maiga, B. Fofana, I. Sagara, D. Dembele, A. Dara et al., No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali, Am J Trop Med Hyg, vol.87, pp.23-31, 2012.

B. R. Ogutu, K. O. Onyango, N. Koskei, E. K. Omondi, J. M. Ongecha et al., Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study, Malar J, vol.13, p.33, 2014.

V. Baraka, H. Tinto, I. Valea, R. Fitzhenry, C. Delgado-ratto et al., In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso, Antimicrob Agents Chemother, vol.59, pp.734-741, 2015.

N. Wurtz, B. Fall, A. Pascual, M. Fall, E. Baret et al., Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin, Antimicrob Agents Chemother, vol.58, pp.7032-7072, 2014.

J. B. Lekana-douki, S. Boutamba, R. Zatra, S. Edou, H. Ekomy et al., Increased prevalence of the Plasmodium falciparum Pfmdr1 86 N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine, Infect Genet Evol, vol.11, pp.512-519, 2011.

N. O. Duah, S. A. Matrevi, D. K. Souza, D. D. Binnah, M. M. Tamakloe et al., Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy, Malar J, vol.12, p.377, 2013.

S. M. Taylor, C. M. Parobek, D. Conti, D. K. Kayentao, K. Coulibaly et al., Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study, J Infect Dis, vol.211, pp.680-688, 2015.

M. Venkatesan, N. B. Gadalla, K. Stepniewska, P. Dahal, C. Nsanzabana et al., Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine, Am J Trop Med Hyg, vol.91, pp.833-876, 2014.